Article
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Antimicrobial agents and chemotherapy - 1 Nov 2006
Hope William W, Warn Peter A, Sharp Andrew, Howard Susan, Kasai Miki, Louie Arnold, Walsh Thomas J, Drusano George L, Denning David W
Abstract excerpt
Drug exposure or pharmacodynamic breakpoints refer to a magnitude of drug exposure which separates a population into groups with high and low probabilities of attaining a desired outcome. We used a pharmacodynamic model of disseminated candidiasis to define an in vivo drug exposure breakpoint for flucytosine (5FC) against Candida albicans. The results were bridged to humans by using population pharmacokinetics...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.